DAPA-HF, EMPEROR-Reduced, and others, as SOLOIST-WHF trials have investigated the combined SGLT2 and SGLT1 inhibitor in T2DM patients hospitalized for HF. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.